An insight into the antifungal pipeline: Selected new molecules and beyond

Luis Ostrosky-Zeichner, Arturo Casadevall, John N Galgiani, Frank C. Odds, John H. Rex

Research output: Contribution to journalArticle

241 Citations (Scopus)

Abstract

Invasive fungal infections are increasing in incidence and are associated with substantial mortality. Improved diagnostics and the availability of new antifungals have revolutionized the field of medical mycology in the past decades. This Review focuses on recent developments in the antifungal pipeline, concentrating on promising candidates such as new azoles, polyenes and echinocandins, as well as agents such as nikkomycin Z and the sordarins. Developments in vaccines and antibody-based immunotherapy are also discussed. Few therapeutic products are currently in active development, and progression of therapeutic agents with fungus-specific mechanisms of action is of key importance.

Original languageEnglish (US)
Pages (from-to)719-727
Number of pages9
JournalNature Reviews Drug Discovery
Volume9
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Echinocandins
Mycology
Polyenes
Azoles
Immunotherapy
Fungi
Vaccines
Mortality
Antibodies
Incidence
Therapeutics
nikkomycin
sordarin
Invasive Fungal Infections

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

An insight into the antifungal pipeline : Selected new molecules and beyond. / Ostrosky-Zeichner, Luis; Casadevall, Arturo; Galgiani, John N; Odds, Frank C.; Rex, John H.

In: Nature Reviews Drug Discovery, Vol. 9, No. 9, 09.2010, p. 719-727.

Research output: Contribution to journalArticle

Ostrosky-Zeichner, Luis ; Casadevall, Arturo ; Galgiani, John N ; Odds, Frank C. ; Rex, John H. / An insight into the antifungal pipeline : Selected new molecules and beyond. In: Nature Reviews Drug Discovery. 2010 ; Vol. 9, No. 9. pp. 719-727.
@article{60de8c6c3ac84654a9be246a9a4d673a,
title = "An insight into the antifungal pipeline: Selected new molecules and beyond",
abstract = "Invasive fungal infections are increasing in incidence and are associated with substantial mortality. Improved diagnostics and the availability of new antifungals have revolutionized the field of medical mycology in the past decades. This Review focuses on recent developments in the antifungal pipeline, concentrating on promising candidates such as new azoles, polyenes and echinocandins, as well as agents such as nikkomycin Z and the sordarins. Developments in vaccines and antibody-based immunotherapy are also discussed. Few therapeutic products are currently in active development, and progression of therapeutic agents with fungus-specific mechanisms of action is of key importance.",
author = "Luis Ostrosky-Zeichner and Arturo Casadevall and Galgiani, {John N} and Odds, {Frank C.} and Rex, {John H.}",
year = "2010",
month = "9",
doi = "10.1038/nrd3074",
language = "English (US)",
volume = "9",
pages = "719--727",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - An insight into the antifungal pipeline

T2 - Selected new molecules and beyond

AU - Ostrosky-Zeichner, Luis

AU - Casadevall, Arturo

AU - Galgiani, John N

AU - Odds, Frank C.

AU - Rex, John H.

PY - 2010/9

Y1 - 2010/9

N2 - Invasive fungal infections are increasing in incidence and are associated with substantial mortality. Improved diagnostics and the availability of new antifungals have revolutionized the field of medical mycology in the past decades. This Review focuses on recent developments in the antifungal pipeline, concentrating on promising candidates such as new azoles, polyenes and echinocandins, as well as agents such as nikkomycin Z and the sordarins. Developments in vaccines and antibody-based immunotherapy are also discussed. Few therapeutic products are currently in active development, and progression of therapeutic agents with fungus-specific mechanisms of action is of key importance.

AB - Invasive fungal infections are increasing in incidence and are associated with substantial mortality. Improved diagnostics and the availability of new antifungals have revolutionized the field of medical mycology in the past decades. This Review focuses on recent developments in the antifungal pipeline, concentrating on promising candidates such as new azoles, polyenes and echinocandins, as well as agents such as nikkomycin Z and the sordarins. Developments in vaccines and antibody-based immunotherapy are also discussed. Few therapeutic products are currently in active development, and progression of therapeutic agents with fungus-specific mechanisms of action is of key importance.

UR - http://www.scopus.com/inward/record.url?scp=77956343542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956343542&partnerID=8YFLogxK

U2 - 10.1038/nrd3074

DO - 10.1038/nrd3074

M3 - Article

C2 - 20725094

AN - SCOPUS:77956343542

VL - 9

SP - 719

EP - 727

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 9

ER -